Table 3.
Studies of HCC cohorts: proportions of MASLD-HCC patients without cirrhosis.
| Ref. | Study Design | Years Studied | Country | Size of Cohort | Proportion with Condition | Proportion without Cirrhosis |
|---|---|---|---|---|---|---|
| [55] | Retrospective observational study of patients with confirmed HCC in the U.S. Veterans Administration | 2005–2010 | U.S. | 1500 patients | Without cirrhosis overall: 13% | |
| MASLD: 8% | 34.6% | |||||
| [56] | Retrospective observational study of patients with histologically proven MASH who developed HCC | 1993–2010 | Japan | 87 patients | MASH: 100% | 49% |
| [57] | Multi-centre prospective observational study of patients with HCC with either HCV or MASLD | 2010–2012 | Italy | 756 patients | HCV: 81% | 2.8% |
| MASLD: 19% | 46.2% | |||||
| [30] | Retrospective evaluation of patients with verified HCC via U.S. healthcare insurance database | 2002–2008 | U.S. | 4406 patients | Without cirrhosis overall: 25% | |
| MASLD: 59% | 54% | |||||
| [32] | Retrospective population-based study of patients within Medicare-linked HCC registry | 2004–2009 | U.S. | 4929 patients | MASLD: 9% annual increase from 2004 to 2009 (from 14.4 to 20.3%) | Not able to assess due to data |
| [58] | Prospective cohort study of patients with HCC referred to a single tertiary liver unit | 2000–2010 | U.K. | 632 patients | MASLD: 35% in 2010, increased from none/undefined in 2000 | 22.5% |
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MASH, metabolic dysfunction-associated steatohepatitis;.MASLD, metabolic dysfunction associated steatotic liver disease.